Liu Xiaofeng, Hu Jialu, Zhang Xia, Fan Daiming
Department of Gastroenterology, General Hospital of Jinan Military Region, Jinan 250031, China.
Chin Med J (Engl). 2002 Oct;115(10):1513-6.
To establish attenuated Salmonella typhimurium producing Helicobacter pylori (H. pylori) urease subunit B (UreB) and determine whether it could be used as an oral vaccine against H. pylori.
H. pylori (SS1 strain) UreB gene fragment amplified by PCR was cloned into the prokaryotic expression vector pTC01 after sequencing, and then transformed into attenuated Salmonella typhimurium SL3261 to acquire SL3261/pTC01-UreB. The expression of H. pylori UreB in SL3261 was detected by Western blot. Twelve weeks after oral immunization of mice, antibody responses were evaluated using serum and intestinal fluid by ELISA assay. Interferon-gamma (IFN-gamma) and interleukin-10 (IL-10) in the supernatant of spleen cells culture were also assessed by ELISA. In vitro stability of pTC01-UreB plasmid in SL3261 was confirmed by growing in Luria Broth (LB) medium to 80 generations.
The UreB gene fragment amplified by PCR was consistent with the sequence of the H. pylori UreB as evidenced by sequence analysis. Enzyme digestion revealed that the correct pTC01-UreB was obtained. Western blot showed that a 61kDa protein was expressed in SL3261/pTC01-UreB, which could be recognized by anti-H. pylori UreB antiserum. After 80 generations of continuous culture, the recombinant plasmid pTC01-UreB was stable in SL3261 and had no obvious toxicity. Multiple oral immunizations with SL3261/pTC01-UreB could significantly induce H. pylori-specific mucosal IgA response as well as serum IgG response. Moreover, there were significant increases of IFN-gamma and IL-10 in the SL3261/pTC01-UreB group. Finally, no obvious side effects for mice and no change in gastric inflammation were observed.
Attenuated Salmonella typhimurium expressing H. pylori UreB may be used as oral vaccine against H. pylori infection.
构建表达幽门螺杆菌(H. pylori)尿素酶亚基B(UreB)的减毒鼠伤寒沙门菌,并确定其是否可作为抗幽门螺杆菌的口服疫苗。
通过PCR扩增幽门螺杆菌(SS1株)UreB基因片段,测序后克隆至原核表达载体pTC01,再将其转化至减毒鼠伤寒沙门菌SL3261中,获得SL3261/pTC01-UreB。采用Western blot检测幽门螺杆菌UreB在SL3261中的表达情况。小鼠经口服免疫12周后,通过ELISA检测血清和肠液中的抗体反应。同时,采用ELISA检测脾细胞培养上清中的干扰素-γ(IFN-γ)和白细胞介素-10(IL-10)。通过在Luria Broth(LB)培养基中传代培养80代,确认pTC01-UreB质粒在SL3261中的体外稳定性。
序列分析表明,PCR扩增得到的UreB基因片段与幽门螺杆菌UreB序列一致。酶切鉴定显示获得了正确的pTC01-UreB。Western blot结果表明,SL3261/pTC01-UreB中表达了一种61kDa的蛋白,可被抗幽门螺杆菌UreB抗血清识别。连续传代培养80代后,重组质粒pTC01-UreB在SL3261中稳定,且无明显毒性。多次口服SL3261/pTC01-UreB可显著诱导幽门螺杆菌特异性黏膜IgA反应以及血清IgG反应。此外,SL3261/pTC01-UreB组中IFN-γ和IL-10显著增加。最后,未观察到小鼠有明显副作用,胃炎症也无变化。
表达幽门螺杆菌UreB的减毒鼠伤寒沙门菌可作为抗幽门螺杆菌感染的口服疫苗。